Quantcast

Latest VIVUS Inc. Stories

2011-05-31 10:05:00

MOUNTAIN VIEW, Calif., May 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in Istanbul, Turkey. ECO is the official obesity congress of The European Association for the Study of Obesity (EASO). ECO is regularly attended by more than 2500 participants from over 75 countries and is considered to be the most important annual scientific event on obesity in Europe....

2011-05-25 05:00:00

MOUNTAIN VIEW, Calif., May 25, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in patients following a radical prostatectomy. The study (REVIVE-RP, TA-303) met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements...

2011-05-20 05:45:00

MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be held May 25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention & Exhibition Center in Istanbul, Turkey. The details of the presentations are as follows: Oral presentation: Friday, May 27 - Novel Drugs Session, Presentation time 17:15-17:30 (local time)...

2011-05-17 11:30:00

MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C. Laurence Belkoff, DO, FACOS, Chairman of the Department of Specialty Surgeries and the Division of...

2011-05-13 05:45:00

MOUNTAIN VIEW, Calif., May 13, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that data on avanafil, its investigational drug candidate, will be featured in a late breaking oral presentation at the American Urological Association (AUA) 2011 Annual Meeting, being held May 14-19, 2011 in Washington, D.C. Following are details about the presentation: The oral presentation will be given at the Walter E. Washington Convention Center in Washington, D.C., on Tuesday, May 17,...

2011-04-29 05:45:00

MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May. The conference presentation schedule is as follows: Deutsche Bank Health Care Conference May 4, 2011 at 11:20 a.m. ET Presented by: Timothy Morris, chief financial officer InterContinental Boston, Boston, MA JMP...

2011-04-11 05:45:00

MOUNTAIN VIEW, Calif., April 11, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US. Data published in the peer-reviewed journal provided an in-depth look at weight loss and improvements in the full spectrum of co-morbidities studied as secondary endpoints, including cardiovascular,...

2011-04-04 05:45:00

MOUNTAIN VIEW, Calif., April 4, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced long-term data that demonstrated patients treated with the investigational drug QNEXA® for two years showed reductions in blood pressure and the use of antihypertensive medications as well as improvements in lipid levels following significant reductions in weight loss as compared to those in the placebo group over two years. The data - additional results from the SEQUEL study...

2011-03-29 05:45:00

MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference. The VIVUS presentation will take place at the Palace Hotel in New York, New York on Tuesday, April 5, 2011 at 2:00 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

2011-02-28 15:00:00

MOUNTAIN VIEW, Calif., Feb. 28, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its highlights and financial results for the fourth quarter and year ended December 31, 2010. 2010 Highlights In the QNEXA investigational drug development program, we successfully completed the two-year SEQUEL study, an extension study in 675 patients from the CONQUER study. Results...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.